HOME Top Market Reports Parkinson's Disease Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) - Global Forecast to 2022

Parkinson's Disease Treatment Market by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, MAO-Inhibitors), Distribution Channel (Hospital, Online, Retail Pharmacies), Patient Care Setting (Hospitals, Clinics) - Global Forecast to 2022

By: marketsandmarkets.com
Publishing Date: October 2017
Report Code: PH 5674

 

  Speak to Analyst Enquiry Before Buying Webinar
purchase report
download pdf  request for customisation


The Parkinson's disease treatment market was valued at USD 3.99 Billion in 2016 and expected to grow at a CAGR of 6.1% from 2017 to 2022 to reach USD 5.69 Billion in 2022.

Years considered in this report:

  • 2016 – Base Year
  • 2017 – Estimated Year
  • 2022 – Projected Year

The objectives of this study are as follows:

  • To define, describe, and forecast the global Parkinsons disease therapeutic drugs market by drug class, distribution channel, treatment facility, and region
  • To provide detailed information regarding the major factors influencing market growth (drivers, restraints, and opportunities)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia, and the Rest of the World (RoW)
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as product launches, agreements, expansions, acquisitions, and other developments in the global Parkinsons disease therapeutic drugs market

Research Methodology

Top-down and bottom-up approaches were used to estimate and validate the size of the global Parkinson's disease treatment market and to estimate the size of various other dependent submarkets. The overall market size was used in the top-down approach to estimate the sizes of other individual markets (mentioned in the market segmentation—by drug class, distribution channel, patient care setting, and region) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained. Various secondary sources referred to for this research study include publications from government sources such as the white papers; articles from recognized authors; gold standard and silver standard websites, directories, and databases; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations have been used to identify and collect information useful for this extensive commercial study of the Parkinson's disease treatment market. Primary sources such as experts from related industries and suppliers have been interviewed to obtain and verify critical information as well as to assess prospects of the Parkinson's disease treatment market. The breakdown of profiles of primaries is shown in the figure below:

Parkinsons Disease Treatment Market

To know about the assumptions considered for the study, download the pdf brochure

Key players operating in the Parkinson's disease treatment market include Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), UCB (Belgium), Valeant Pharmaceuticals (Canada), Acadia (US), Sun Pharma (India), Wockhardt (India), Dr. Reddy’s (India), Intas (India), US WorldMeds (US), Zydus Cadila (India), Cipla (India), Strides (India), 1 A Pharma (India), and Upsher-Smith (US).

Target Audience for this Report:

  • Parkinsons disease treatment product manufacturers
  • Parkinsons disease treatment dealers and suppliers
  • Human identification service providers
  • Parkinsons disease associations
  • Academic institutions
  • Venture capitalists
  • Consulting firms
  • Government bodies

Value Addition for the Buyer:

This report aims to provide insights into the global Parkinson's disease treatment market. It provides valuable information on the market classification by drug class, distribution channels, and patient care setting. Details on regional markets for these segments have also been presented in this report. In addition, leading players in the market are profiled to understand the strategies undertaken by them to be competitive in this market.

Scope of the Report:

This report categorizes the Parkinson's disease treatment market into the following segments:

Parkinson's Disease Treatment Market: By Drug Class

  • Levodopa/carbidopa
  • Dopamine Receptor Agonists
  • MAO-Inhibitors
  • COMT-inhibitors
  • Anticholinergics
  • Other Drugs

Parkinson's Disease Treatment Market: By Distribution Channel

  • Hospital Pharmacies
  • Retailer Pharmacies
  • Online Pharmacies

Parkinson's Disease Treatment Market: By Patient Care Setting

  • Hospitals
  • Clinics

Parkinson's Disease Treatment Market: By Region

  • North America
    • US
    • Canada
  • Europe
  • Asia
    • China
    • Japan
    • Rest of Asia (RoA)
  • Rest of the World (RoW)

Customization Options:

  • Company Information: Detailed company profiles of five or more market players
  • Opportunities Assessment: A detailed report underlining the various growth opportunities presented in the market

Table of Contents

1 Parkinson's Disease Treatment Market: Introduction (Page No. - 12)
    1.1 Objectives of the Study
    1.2 Market Definition
           1.2.1 Markets Covered
           1.2.2 Years Considered for the Study
    1.3 Currency
    1.4 Limitations
    1.5 Stakeholders

2 Parkinson's Disease Treatment Market: Research Methodology (Page No. - 15)
    2.1 Research Data
           2.1.1 Secondary Data
                    2.1.1.1 Key Data From Secondary Sources
           2.1.2 Primary Data
                    2.1.2.1 Key Data From Primary Sources
    2.2 Market Size Estimation
           2.2.1 Bottom-Up Approach
           2.2.2 Top-Down Approach
    2.3 Market Breakdown and Data Triangulation
    2.4 Assumptions for the Study

3 Parkinson's Disease Treatment Market: Executive Summary (Page No. - 23)

4 Parkinson's Disease Treatment Market: Premium Insights (Page No. - 27)
    4.1 Parkinson’s Disease Treatment Market Overview
    4.2 Geographic Analysis: Parkinson’s Disease Treatment Market, By Drug Class
    4.3 Geographic Analysis of the Parkinson’s Disease Treatment Market, By Country
    4.4 Geographic Analysis of the Parkinson’s Disease Treatment Market

5 Parkinson's Disease Treatment Market: Overview (Page No. - 31)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 Growth in Aging Population and the Associated Increase in the Prevalence of Parkinson’s Disease
                    5.2.1.2 Government Funding for Research
           5.2.2 Restraints
                    5.2.2.1 Availability of Alternative Treatments
           5.2.3 Opportunities
                    5.2.3.1 Patent Expiry of Branded Drugs
                    5.2.3.2 Strong Drug Pipeline

6 Parkinson’s Disease Treatment Market, By Drug Class (Page No. - 36)
    6.1 Introduction
    6.2 Carbidopa/Levodopa
    6.3 Dopamine Receptor Agonists
    6.4 Mao Inhibitors
    6.5 Comt Inhibitors
    6.6 Anticholinergics
    6.7 Other Drugs

7 Parkinson’s Disease Treatment Market, By Distribution Channel (Page No. - 47)
    7.1 Introduction
    7.2 Hospital Pharmacies
    7.3 Retailer Pharmacies
    7.4 Online Pharmacies

8 Parkinson’s Disease Treatment Market, By Patient Care Setting (Page No. - 52)
    8.1 Introduction
    8.2 Hospitals
    8.3 Clinics

9 Parkinson’s Disease Treatment Market, By Region (Page No. - 57)
    9.1 Introduction
    9.2 Europe
    9.3 North America
           9.3.1 U.S.
           9.3.2 Canada
    9.4 Asia
           9.4.1 Japan
           9.4.2 China
           9.4.3 Rest of Asia
    9.5 Rest of the World

10 Company Profiles (Page No. - 77)
(Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, Recent Developments)*
     10.1 GSK
     10.2 Merck
     10.3 Novartis
     10.4 Teva
     10.5 Boehringer Ingelheim
     10.6 Impax
     10.7 Abbvie
     10.8 Valeant Pharmaceuticals
     10.9 Lundbeck
     10.10 Sun Pharma
     10.11 Wockhardt
     10.12 Acadia
     10.13 UCB

*Details on Marketsandmarkets View, Overview, Products Offered, Product Offering Scorecard, Business Strategy Scorecard, and Recent Developments Might Not Be Captured in Case of Unlisted Companies.

11 Appendix (Page No. - 105)
     11.1 Insights of Industry Experts
     11.2 Discussion Guide
     11.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
     11.4 Introducing RT: Real-Time Market Intelligence
     11.5 Available Customizations
     11.6 Related Reports
     11.7 Author Details


List of Tables (66 Tables)

Table 1 Global Parkinson’s Disease Treatment Market Summary
Table 2 Ageing Population, By Region, 2015 vs 2030
Table 3 Parkinson’s Disease Treatment Market: List of Pipeline Drugs
Table 4 Parkinson’s Disease Treatment Market, By Drug Class, 2016–2022 (USD Million)
Table 5 Carbidopa/Levodopa Market, By Region, 2015–2022 (USD Million)
Table 6 North America: Carbidopa/Levodopa Market, By Country, 2015–2022 (USD Million)
Table 7 Asia: Carbidopa/Levodopa Market, By Country, 2015–2022 (USD Million)
Table 8 Dopamine Receptor Agonists Market, By Region, 2015–2022 (USD Million)
Table 9 North America: Dopamine Receptor Agonists Market, By Country, 2015–2022 (USD Million)
Table 10 Asia: Dopamine Receptor Agonists Market, By Country, 2015–2022 (USD Million)
Table 11 Mao Inhibitors Market, By Region, 2015–2022 (USD Million)
Table 12 North America: Mao Inhibitors Market, By Country, 2015–2022 (USD Million)
Table 13 Asia: Mao Inhibitors Market, By Country, 2015–2022 (USD Million)
Table 14 Comt Inhibitors Market, By Region, 2015–2022 (USD Million)
Table 15 North America: Comt Inhibitors Market, By Country, 2015–2022 (USD Million)
Table 16 Asia: Comt Inhibitors Market, By Country, 2015–2022 (USD Million)
Table 17 Anticholinergics Market, By Region, 2015–2022 (USD Million)
Table 18 North America: Anticholinergics Market, By Country, 2015–2022 (USD Million)
Table 19 Asia: Anticholinergics Market, By Country, 2015–2022 (USD Million)
Table 20 Other Drugs Market, By Region, 2015–2022 (USD Million)
Table 21 North America: Other Drugs Market, By Country, 2015–2022 (USD Million)
Table 22 Asia: Other Drugs Market, By Country, 2015–2022 (USD Million)
Table 23 Parkinson’s Disease Treatment Market, By Distribution Channel, 2015–2022 (USD Million)
Table 24 Parkinson’s Disease Treatment Market for Hospital Pharmacies, By Region, 2015–2022 (USD Million)
Table 25 North America: Parkinson’s Disease Treatment Market for Hospital Pharmacies, By Country, 2015–2022 (USD Million)
Table 26 Parkinson’s Disease Treatment Market for Retail Pharmacies, By Region, 2015–2022 (USD Million)
Table 27 North America: Parkinson’s Disease Treatment Market for Retailer Pharmacies, By Country, 2015–2022 (USD Million)
Table 28 Parkinson’s Disease Treatment Market for Online Pharmacies, By Region, 2015–2022 (USD Million)
Table 29 North America: Parkinson’s Disease Treatment Market for Online Pharmacies, By Country, 2015–2022 (USD Million)
Table 30 Parkinson’s Disease Treatment Market, By Patient Care Setting, 2015–2022 (USD Million)
Table 31 Parkinson’s Disease Treatment Market for Hospitals, By Region, 2015–2022 (USD Million)
Table 32 North America: Parkinson’s Disease Treatment Market for Hospitals, By Country, 2015–2022 (USD Million)
Table 33 Asia: Parkinson’s Disease Treatment Market for Hospitals, By Country, 2015–2022 (USD Million)
Table 34 Parkinson’s Disease Treatment Market for Clinics, By Region, 2015–2022 (USD Million)
Table 35 North America: Parkinson’s Disease Treatment Market for Clinics, By Country, 2015–2022 (USD Million)
Table 36 Asia: Parkinson’s Disease Treatment Market for Clinics, By Country, 2015–2022 (USD Million)
Table 37 Global Parkinson’s Disease Treatment Market, By Region, 2015–2022 (USD Million)
Table 38 Europe: Parkinson’s Disease Treatment Market, By Drug Class, 2015–2022 (USD Million)
Table 39 Europe: Parkinson’s Disease Treatment Market, By Distribution Channel, 2015–2022 (USD Million)
Table 40 Europe: Parkinson’s Disease Treatment Market, By Patient Care Setting, 2015–2022 (USD Million)
Table 41 North America: Parkinson’s Disease Treatment Market, By Country, 2015–2022 (USD Million)
Table 42 North America: Parkinson’s Disease Treatment Market, By Drug Class, 2015–2022 (USD Million)
Table 43 North America: Parkinson’s Disease Treatment Market, By Distribution Channel, 2015–2022 (USD Million)
Table 44 North America: Parkinson’s Disease Treatment Market, By Patient Care Setting, 2015–2022 (USD Million)
Table 45 US: Parkinson’s Disease Treatment Market, By Drug Class, 2015–2022 (USD Million)
Table 46 US: Parkinson’s Disease Treatment Market, By Distribution Channel, 2015–2022 (USD Million)
Table 47 US: Parkinson’s Disease Treatment Market, By Patient Care Setting, 2015–2022 (USD Million)
Table 48 Canada: Parkinson’s Disease Treatment Market, By Drug Class, 2015–2022 (USD Million)
Table 49 Canada: Parkinson’s Disease Treatment Market, By Distribution Channel, 2015–2022 (USD Million)
Table 50 Canada: Parkinson’s Disease Treatment Market, By Patient Care Setting, 2015–2022 (USD Million)
Table 51 Asia: Parkinson’s Disease Treatment Market, By Country, 2015–2022 (USD Million)
Table 52 Asia: Parkinson’s Disease Treatment Market, By Drug Class, 2015–2022 (USD Million)
Table 53 Asia: Parkinson’s Disease Treatment Market, By Distribution Channel, 2015–2022 (USD Million)
Table 54 Asia: Parkinson’s Disease Treatment Market, By Patient Care Setting, 2015–2022 (USD Million)
Table 55 Japan: Parkinson’s Disease Treatment Market, By Drug Class, 2015–2022 (USD Million)
Table 56 Japan: Parkinson’s Disease Treatment Market, By Distribution Channel, 2015–2022 (USD Million)
Table 57 Japan: Parkinson’s Disease Treatment Market, By Patient Care Setting, 2015–2022 (USD Million)
Table 58 China: Parkinson’s Disease Treatment Market, By Drug Class, 2015–2022 (USD Million)
Table 59 China: Parkinson’s Disease Treatment Market, By Distribution Channel, 2015–2022 (USD Million)
Table 60 China: Parkinson’s Disease Treatment Market, By Patient Care Setting, 2015–2022 (USD Million)
Table 61 RoA: Parkinson’s Disease Treatment Market, By Drug Class, 2015–2022 (USD Million)
Table 62 RoA: Parkinson’s Disease Treatment Market, By Distribution Channel, 2015–2022 (USD Million)
Table 63 RoA: Parkinson’s Disease Treatment Market, By Patient Care Setting, 2015–2022 (USD Million)
Table 64 RoW: Parkinson’s Disease Treatment Market, By Drug Class, 2015–2022 (USD Million)
Table 65 RoW: Parkinson’s Disease Treatment Market, By Distribution Channel, 2015–2022 (USD Million)
Table 66 RoW: Parkinson’s Disease Treatment Market, By Patient Care Setting, 2015–2022 (USD Million)


List of Figures (33 Figures)

Figure 1 Global Parkinson’s Disease Treatment Market
Figure 2 Research Design
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Parkinson’s Disease Treatment Market: Bottom-Up Approach
Figure 5 Parkinson’s Disease Treatment Market: Top-Down Approach
Figure 6 Data Triangulation Methodology
Figure 7 Global Parkinson’s Disease Treatment Market, By Drug Class, 2017 vs 2022
Figure 8 Global Parkinson’s Disease Treatment Market, By Distribution Channel, 2017 vs 2022
Figure 9 Global Parkinson’s Disease Treatment Market, By Patient Care Setting, 2017 vs 2022
Figure 10 Global Parkinson’s Disease Treatment Market, By Region, 2017 vs 2022
Figure 11 Increasing Prevalence of Parkinson’s Disease to Drive the Growth of the Parkinson’s Disease Treatment Market
Figure 12 Carbidopa/Levodopa Segment and Japan to Account for the Largest Market Share in 2017
Figure 13 Japan to Register the Highest CAGR During the Forecast Period
Figure 14 Europe to Register the Highest Markest Share During the Forecast Period
Figure 15 Parkinson’s Disease Treatment Market: Drivers, Restraints, and Opportunities
Figure 16 Hospital Pharmacies to Continue to Dominate the Parkinson’s Disease Treatment Market During the Forecast Period
Figure 17 Hospitals Segment to Dominate the Parkinson’s Disease Treatment Market During the Forecast Period
Figure 18 Parkinson’s Disease Treatment Market: Geographic Snapshot (2017-2022)
Figure 19 North America: Market Snapshot
Figure 20 Asia: Market Snapshot
Figure 21 GSK .: Company Snapshot
Figure 22 Merck: Company Snapshot
Figure 23 Novartis: Company Snapshot
Figure 24 Teva : Company Snapshot
Figure 25 Boehringer Ingelheim: Company Snapshot
Figure 26 Impax: Company Snapshot
Figure 27 Abbvie.: Company Snapshot
Figure 28 Valeant: Company Snapshot
Figure 29 Lundbeck: Company Snapshot
Figure 30 Sun Pharma: Company Snapshot
Figure 31 Wockhardt: Company Snapshot
Figure 32 Acadia.: Company Snapshot
Figure 33 UCB: Company Snapshot

Parkinsons disease treatment is used to treat the symptoms of Parkinsons disease, generally, medication is the first line treatment for this disease. The global Parkinson's disease treatment market is expected to reach USD 5.69 Billion by 2022 from USD 4.24 Billion in 2017, at a CAGR of 6.1%. Rising geriatric population and government funding for research on Parkinsons disease are the driving factors for this market.

The Parkinson's disease treatment market is segmented on the basis of drug class, distribution channel, patient care setting, and region. On the basis of drug class, the Parkinson's disease treatment market is segmented into carbidopa/levodopa, dopamine receptor agonists, MAO-inhibitors, COMT-inhibitors, anticholinergics and other drugs. The carbidopa/levodopa segment is expected to account for the largest share of the market in 2017. The growth in this segment is primarily attributed to the potency of the drug.

By distribution channel, the Parkinson's disease treatment market is segmented into hospital pharmacies, retailer pharmacies, and online pharmacies. In 2017, the hospital pharmacies segment accounted for the largest share of the market. Increasing number of patient visits to the hospital due to the availability of diagnostic laboratories and presence of skilled neurologists are driving the growth of hospital pharmacies segment.

On the basis of patient care setting, the Parkinson's disease treatment market is segmented into hospitals and clinics. In 2017, hospitals are expected to account for the largest share of the Parkinson's disease treatment market. Robust health infrastructure and presence of skilled neurologists are the driving factors for hospital segment.

Parkinsons Disease Treatment Market

By region, the Parkinson's disease treatment market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). The market is dominated by Europe, followed by North America, however, the Asian region is expected to witness the highest growth during the forecast period. Asia is expected to witness the highest CAGR, with the growth in this market centered at Japan, China, and India. The increasing number of generic drug manufacturers and rising aging populaion across are key factors driving the Parkinson's disease treatment market in Asia. However, availability of alternative treatments is going to restrain this market.

Teva (Israel), AbbVie (US), Boehringer Ingelheim (Germany) Lundbeck (Denmark), Acadia (US), Sun Pharma (India), US WorldMeds (US), Dr. Reddy’s (India), are the top players in this market. These companies have a broad product portfolio with comprehensive features and a strong geographical presence.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit https://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports



Access reports on all high
growth Pharmaceuticals Markets on KnowledgeStore
Request Demo